Aperio Group LLC trimmed its holdings in AngioDynamics, Inc. (NASDAQ:ANGO) by 12.8% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,515 shares of the medical instruments supplier’s stock after selling 1,844 shares during the quarter. Aperio Group LLC’s holdings in AngioDynamics were worth $246,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds and other institutional investors also recently made changes to their positions in ANGO. Texas Permanent School Fund raised its position in shares of AngioDynamics by 3.8% during the first quarter. Texas Permanent School Fund now owns 25,215 shares of the medical instruments supplier’s stock valued at $576,000 after buying an additional 923 shares during the last quarter. Nisa Investment Advisors LLC increased its position in AngioDynamics by 100.0% in the second quarter. Nisa Investment Advisors LLC now owns 2,200 shares of the medical instruments supplier’s stock worth $43,000 after purchasing an additional 1,100 shares during the last quarter. Financial Gravity Wealth Inc. bought a new stake in AngioDynamics in the second quarter worth $33,000. Strs Ohio increased its position in AngioDynamics by 5.3% in the second quarter. Strs Ohio now owns 36,000 shares of the medical instruments supplier’s stock worth $708,000 after purchasing an additional 1,800 shares during the last quarter. Finally, Rhumbline Advisers increased its position in AngioDynamics by 1.7% in the first quarter. Rhumbline Advisers now owns 110,139 shares of the medical instruments supplier’s stock worth $2,518,000 after purchasing an additional 1,882 shares during the last quarter. 99.51% of the stock is currently owned by hedge funds and other institutional investors.
In other news, Director Kevin J. Gould sold 13,650 shares of the stock in a transaction that occurred on Tuesday, July 16th. The stock was sold at an average price of $21.45, for a total transaction of $292,792.50. Following the transaction, the director now owns 61,774 shares in the company, valued at approximately $1,325,052.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 3.60% of the company’s stock.
Several equities research analysts recently weighed in on the stock. Zacks Investment Research upgraded shares of AngioDynamics from a “sell” rating to a “hold” rating and set a $20.00 price target on the stock in a research report on Tuesday, June 4th. TheStreet lowered shares of AngioDynamics from a “b” rating to a “c” rating in a research note on Monday, July 29th. ValuEngine raised shares of AngioDynamics from a “hold” rating to a “buy” rating in a research note on Tuesday, July 2nd. Finally, BidaskClub lowered shares of AngioDynamics from a “hold” rating to a “sell” rating in a research note on Saturday, August 31st. One research analyst has rated the stock with a sell rating, two have issued a hold rating and one has given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $21.50.
AngioDynamics stock traded up $0.09 during trading hours on Friday, reaching $18.48. The stock had a trading volume of 16,477 shares, compared to its average volume of 139,695. The business’s 50 day moving average price is $19.22 and its 200-day moving average price is $20.45. The company has a market cap of $679.65 million, a price-to-earnings ratio of 22.27 and a beta of 0.72. AngioDynamics, Inc. has a 52 week low of $17.67 and a 52 week high of $25.48. The company has a debt-to-equity ratio of 0.20, a current ratio of 4.30 and a quick ratio of 3.75.
AngioDynamics (NASDAQ:ANGO) last issued its earnings results on Wednesday, July 10th. The medical instruments supplier reported $0.25 EPS for the quarter, missing the Zacks’ consensus estimate of $0.26 by ($0.01). AngioDynamics had a net margin of 17.06% and a return on equity of 5.58%. The firm had revenue of $96.30 million during the quarter, compared to analysts’ expectations of $92.34 million. During the same quarter in the prior year, the company earned $0.20 EPS. AngioDynamics’s quarterly revenue was up 9.1% on a year-over-year basis. On average, sell-side analysts forecast that AngioDynamics, Inc. will post 0.27 EPS for the current fiscal year.
AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.
See Also: What is the NASDAQ Stock Market?
Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.